argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in ChinaGlobeNewsWire • 06/30/23
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia GravisGlobeNewsWire • 06/20/23
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor NeuropathyGlobeNewsWire • 06/20/23
Argenx Believes It Might Have 'One Of The Biggest Biologics' Ever — And Shares Are SoaringInvestors Business Daily • 05/18/23
All You Need to Know About argenex SE (ARGX) Rating Upgrade to BuyZacks Investment Research • 05/09/23
argenx Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/04/23
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023GlobeNewsWire • 04/27/23
argenx: Exciting Genmab Partnership, All Eyes On Q1 Earnings And CIDP ReadoutSeeking Alpha • 04/21/23
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual MeetingGlobeNewsWire • 04/18/23
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and OncologyGlobeNewsWire • 04/17/23
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and OncologyGlobeNewsWire • 04/17/23
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia GravisGlobeNewsWire • 03/15/23
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewsWire • 03/02/23
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023GlobeNewsWire • 02/23/23
argenx: Priority Review Voucher Goes To Waste And Why SC Efgartigimod Is ImportantSeeking Alpha • 02/06/23